Sandoz delivers 6% sales growth with Humira biosimilar leading the charge
Fierce Pharma
MAY 7, 2024
With Hyrimoz leading the way, sales of the company’s biosimilars reached $623 million in the first three months of this year. . | After spinning off as a separate business from Novartis, Sandoz is riding the wave of a strong launch of its biosimilar version of AbbVie’s Humira (adalimumab).
Let's personalize your content